Kamada vs Stoke Therapeutics
Stoke Therapeutics reported revenue of $184 million in fiscal 2025, about the same as Kamada's $180 million in fiscal 2025. Kamada's revenue grew 12.1% in its latest year, and Stoke Therapeutics' grew 404.5%. Kamada had an operating margin of 14.5%, against -11.2% at Stoke Therapeutics. Free cash flow was $16 million at Kamada and $45 million at Stoke Therapeutics.
Side by side
| Kamada | Stoke Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $180M | $184M |
| Revenue growth | 12.1% | 404.5% |
| Revenue growth a year, last 5 years | 6.3% | — |
| Gross margin | 42.3% | — |
| Operating margin | 14.5% | −11.2% |
| Net margin | 11.2% | −3.7% |
| Free cash flow | $16M | $45M |
| Free cash flow margin | 8.7% | 24.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $12M | $0M |
| Change in diluted share count | 0.9% | 9.7% |
| Last close | $7.83 | $26.93 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $1.7 million | sold $7.6 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
KamadaStoke Therapeutics
Operating margin
Percent of revenue
KamadaStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
KamadaStoke Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kamada and Stoke Therapeutics pages.